MedTrace Logo

Improved Factor VIII Inhibitor Evaluation

NCT02726139 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2021-02-25

No results posted yet for this study

Summary

Commercial one and two-stage factor VIII assays may not detect some clinically significant inhibitor antibodies. The purpose of the proposed study is to standardize and validate a platelet-based factor VIII activity assay with greater sensitivity to clinically important inhibitory antibodies. Investigators will evaluate the platelet-dependent inhibitory activity vs. conventional inhibitory activity in stored patient plasmas and correlate to bleeding histories

Conditions

Sponsors & Collaborators

  • Shire

    collaborator INDUSTRY

  • Emory University

    collaborator OTHER

  • University of Michigan

    collaborator OTHER

  • Boston VA Research Institute, Inc.

    lead OTHER

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-15
Primary Completion
2021-01-25
Completion
2021-01-25

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02726139 on ClinicalTrials.gov